SEC-FDA Agreement Increases Disclosure Risk for Life Sciences Firms

The U.S. Securities and Exchange Commission (SEC) and the U.S. Food and Drug Administration (FDA) announced a memorandum of understanding on August 31, 2026. This agreement opens nonpublic FDA communications to SEC enforcement staff. The agreement heightens disclosure and insider-trading risks for life sciences companies, according to McDermott Will & Schulte.

The details

The memorandum of understanding establishes formal channels for exchanging nonpublic information between the SEC and FDA. This pact is for three years. It allows SEC enforcement staff access to nonpublic FDA communications. This includes information about FDA-regulated public companies. The agreement aims to accelerate insider trading probes in the biopharma sector. The SEC and FDA signed this memorandum on August 31, 2026.

The mechanism of this agreement involves the direct sharing of information that was previously confidential between the two agencies. Specifically, the SEC will now have access to nonpublic information from the FDA. This information was previously unavailable to the SEC. This access applies to communications related to FDA-regulated public companies. The goal is to enhance the SEC's ability to investigate potential securities law violations. These violations include insider trading and disclosure failures. The agreement specifically targets life sciences companies, according to McDermott Will & Schulte. It provides the SEC with new tools for enforcement actions. The formal channels established by the memorandum facilitate this exchange, ensuring that SEC enforcement staff can obtain relevant FDA data to support their investigations. This structured information sharing is designed to streamline the identification and prosecution of securities law breaches that rely on nonpublic FDA-related data.

Why it matters

The agreement increases the potential for SEC investigations. Life sciences companies must now consider that nonpublic FDA communications could become part of an SEC inquiry. This raises disclosure risks. Companies must assess what information, previously considered confidential within FDA interactions, might now be subject to SEC scrutiny. This could lead to more enforcement suits. It could also lead to bigger and more complicated cases, according to Bloomberg Law News. The expanded access means that the SEC can proactively identify discrepancies or omissions in public disclosures by comparing them with the nonpublic FDA data. This mechanism directly impacts how companies manage and disclose information related to clinical trials, regulatory submissions, and product approvals, as the risk of SEC scrutiny based on internal FDA communications has increased.

Insider trading risks are also heightened. Access to nonpublic FDA information by the SEC could lead to more investigations into trading activity. This applies to individuals with access to sensitive FDA-related data. The agreement facilitates the sharing of information that could be material to investors. This includes information about drug approvals, clinical trials, or regulatory actions. The SEC's ability to pursue insider trading cases is enhanced by this new data access. The second-order effect is that individuals, including company executives, employees, and consultants, who possess nonpublic information about FDA decisions or communications, face increased personal liability if they trade on such information or tip others. The formal channels for information exchange between the SEC and FDA are specifically designed to accelerate these insider trading probes in the biopharma sector. This implies a more efficient process for the SEC to obtain evidence necessary for enforcement actions against those who misuse confidential FDA-related information for financial gain.

This development coincides with the SEC's increased focus on enforcement. The SEC created a dedicated Financial Reporting and Accounting Unit (FRAU). This unit signals a focus on disclosure integrity, accounting fraud, and audit oversight, according to Freshfields. The FRAU is seen as a core fraud enforcement engine, according to Bloomberg Law News. The SEC's enhanced access to FDA information complements these broader enforcement initiatives. It provides another avenue for identifying potential misconduct in the life sciences sector. The establishment of FRAU, alongside the FDA agreement, indicates a strategic shift by the SEC towards more aggressive and comprehensive enforcement, particularly in areas involving financial reporting and material nonpublic information. This combined approach suggests that life sciences companies will face heightened scrutiny not only over their FDA-related disclosures but also their overall financial reporting and accounting practices. The second-order effect here is a potential increase in the number and complexity of enforcement actions against public companies and their auditors, as the SEC leverages both its internal specialized units and external agency agreements to uncover fraud and disclosure failures.

What to watch

Companies in the life sciences sector should monitor SEC enforcement actions. They should also review their internal policies. These policies should address the handling and disclosure of FDA-related information. The three-year duration of the agreement suggests ongoing enforcement activity in this area. The impact on specific companies will become clearer as SEC investigations proceed. Companies should consider enhancing their compliance programs, particularly regarding the flow of information between their regulatory affairs, legal, and investor relations departments. The increased risk environment necessitates proactive measures to ensure that all public disclosures accurately reflect the company's interactions with the FDA and that internal controls prevent the misuse of nonpublic information. The evolving landscape of SEC enforcement, bolstered by inter-agency cooperation and specialized internal units, signals a period of heightened regulatory risk for the life sciences industry.